Biotech entity

Madhavan Balachandran

Person

All 1 tracked stories fall under one category: gene-therapy. Of the tracked stories, 1 of 1 also mention AMT-130, the most common co-covered peer. The tracked stories average 3 original sources each. Madhavan Balachandran appears in 1 tracked Biotech story from August 5, 2026.

Last mentioned: Aug 5, 2026

Entity pulse

Recent coverage · Madhavan Balachandran

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Madhavan Balachandran

All 1 tracked stories fall under one category: gene-therapy. Of the tracked stories, 1 of 1 also mention AMT-130, the most common co-covered peer. The tracked stories average 3 original sources each. Madhavan Balachandran appears in 1 tracked Biotech story from August 5, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Madhavan Balachandran. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. SEC filings and market close

    Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.

  2. Insider sales executed

    Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.

  3. Q1 2026 earnings

    uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.

  4. RBC upgrade

    RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.

Stories mentioning Madhavan Balachandran 1

Madhavan Balachandran is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.